reports
Moody's Ratings upgrades Royalty Pharma's rating to Baa2; outlook is s...
Moody's Ratings (Moody's) upgraded the senior unsecured notes of Royalty Pharma plc ("Royalty Pharma") to Baa2 from Baa3. At the same time, we revised the outlook to stable from positive. The upgrade reflects our expectation that Royalty Pharma will continue to generate strong earnings growth from...
Royalty Pharma Declares Second Quarter 2025 Dividend
Royalty Pharma Declares Second Quarter 2025 Dividend NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on June 10, 2025, to shareholders of record at the close of business on May 16, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from ...
Royalty Pharma to Announce First Quarter 2025 Financial Results on May...
Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025 NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at to obtain conference call information and to view the live webcast. A replay of the conference ca...
Royalty Pharma Appoints Vlad Coric, M.D. to the Company’s Board of Dir...
Royalty Pharma Appoints Vlad Coric, M.D. to the Company’s Board of Directors NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. “I am excited to announce that we are strengthening our Board with...
Royalty Pharma Announces Upcoming Investor Day
Royalty Pharma Announces Upcoming Investor Day NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an Investor Day in New York City on Thursday, September 11, 2025, starting at 8:30 a.m. ET. Royalty Pharma senior executives will provide an update on the company’s plans to drive shareholder value creation through leveraging its unique business model and capabilities in the large and growing market for funding biopharma innovation. The meeting will include live question and answer sessions. Additional details will follow closer t...
Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Confer...
Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 45th Annual Health Care Conference on March 4, 2025 at 2:30 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at . The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharm...
Royalty Pharma Announces R&D Funding Collaboration With Biogen
Royalty Pharma Announces R&D Funding Collaboration With Biogen Royalty Pharma to provide R&D investment of up to $250 million for Biogen’s litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a first-in-class investigational drug candidate in Phase 3 with demonstrated proof-of-concept in both systemic lupus eryth...
Royalty Pharma Reports Q4 and Full Year 2024 Results
Royalty Pharma Reports Q4 and Full Year 2024 Results Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in Q4 2024 and $2,769 million for FY 2024Full year 2025 guidance: Portfolio Receipts expected to be $2,900 to $3,050 million excluding future transactions NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year 2024 and introduced full year 2025 guidanc...
Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds
Royalty Pharma Announces Sale of MorphoSys Development Funding Bonds Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue disciplined capital allocation strategy, including significant share repurchases and royalty acquisitions NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the closing of a transaction to monetize the remaining fixed payments on the MorphoSys Development Funding Bonds for $511 million in upfront cash. This payment, combined with paym...
Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial...
Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025 NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 11, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at to obtain conference call information and to view the live we...
Royalty Pharma to Highlight Accomplishments and Provide Business Updat...
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 43rd Annual J.P. Morgan Healthcare Conference 2024 Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with potential for peak royalties of >$1.2 billion; multiple key upcoming events, including Phase 3 results for pelacarsen Royalty Pharma to benefit from new product launches in 2025, including Servier’s Voranigo, Bristol Myers Squibb’s Cobenfy, Ascendis’ Yorvipath, Syndax and Incyte’s Niktimvo and Geron’s Rytelo NEW YORK, Jan. 1...
Royalty Pharma Announces Transformative Step in Company’s Evolution Wi...
Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLCSignificant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6 billion over ten yearsSimplified structure to benefit shareholders through strengthened shareholder alignment, enhanced governance and increased economic return on investments Board authorized a ...
Royalty Pharma Announces Dividend Increase
Royalty Pharma Announces Dividend Increase NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ordinary share, reflecting a 5% increase in the company’s quarterly dividend over the previous quarter’s dividend. The dividend will be paid on March 10, 2025 to shareholders of record at the close of business on February 21, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading ...
Royalty Pharma to Present at Upcoming Investor Conferences
Royalty Pharma to Present at Upcoming Investor Conferences NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December: 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3 at 12:55 p.m. ETCiti’s 2024 Global Healthcare Conference on Wednesday, December 4 at 1:45 p.m. ET The webcasts will be accessible from Royalty Pharma’s “Events” page at . Webcasts will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 19...
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the Prostate Cancer FoundationThe Prize includes a charitable donation to further fund medical research NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the inaugural Royalty Pharma Prize for Impact in Healthcare, which honors individuals or organizations who positively impact healthcare, was awarded to Micheal Milken. The prize includes a $2...
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 ...
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million RYTELO™ (imetelstat) is FDA approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemiaTransaction increases Royalty Pharma’s synthetic royalty funding to $925 million in 2024, highlighting the significant opportunity for this attractive funding modality NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will acquire a synthetic royalty on U.S. sales of Geron Corporation’s (Nasdaq: GERN) RYTELO for $125 ...
Royalty Pharma Reports Third Quarter 2024 Results
Royalty Pharma Reports Third Quarter 2024 Results Portfolio Receipts growth of 15% to $735 million; Royalty Receipts growth of 15%Net cash provided by operating activities of $704 millionCapital Deployment of approximately $1.2 billion Raising full year 2024 guidance: Portfolio Receipts expected to be $2,750 to $2,800 million NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2024 and raised full year 2024 guidance for Portfolio Receipts. “We delivered strong growth of approximately 15% in Portfolio Rec...
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Roya...
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 million as of June 30 NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that Royalty Pharma has entered into a $350 million synthetic royalty funding agreement with Syndax based on U.S....
Royalty Pharma to Announce Third Quarter 2024 Financial Results on Nov...
Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024 NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2024 financial results on Wednesday, November 6, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at to obtain conference call information and to view the live webcast. A replay of the confere...
Royalty Pharma Declares Fourth Quarter 2024 Dividend
Royalty Pharma Declares Fourth Quarter 2024 Dividend NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on December 10, 2024, to shareholders of record at the close of business on November 15, 2024. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovato...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.